What is Mirum Pharmaceuticals's earnings per share (EPS)?

Mirum Pharmaceuticals (MIRM) reported diluted earnings per share of $-0.47 for fiscal year 2025. This represents a 74.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Mirum Pharmaceuticals Financials

MIRM

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Mirum Pharmaceuticals (MIRM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 47/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Mirum Pharmaceuticals has an operating margin of -4.3%, meaning the company retains $-4 of operating profit per $100 of revenue. This below-average margin results in a low score of 13/100, suggesting thin profitability after operating expenses. This is up from -26.0% the prior year.

Growth

100

Mirum Pharmaceuticals's revenue surged 54.7% year-over-year to $521.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Mirum Pharmaceuticals carries a low D/E ratio of 1.68, meaning only $1.68 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 68/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Mirum Pharmaceuticals's current ratio of 2.67 indicates adequate short-term liquidity, earning a score of 50/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Mirum Pharmaceuticals has a free cash flow margin of 10.5%, earning a moderate score of 51/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Mirum Pharmaceuticals generates a -7.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -39.0% the prior year.

Piotroski F-Score Neutral

4/9

Mirum Pharmaceuticals passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Mixed

-2.39x

For every $1 of reported earnings, Mirum Pharmaceuticals generates $-2.39 in operating cash flow ($55.8M OCF vs -$23.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-1.5x

Mirum Pharmaceuticals earns $-1.5 in operating income for every $1 of interest expense (-$22.1M vs $14.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$521.3M

YoY+54.7%

Mirum Pharmaceuticals generated $521.3M in revenue in fiscal year 2025. This represents an increase of 54.7% from the prior year.

EBITDA

$2.1M

YoY+103.3%

Mirum Pharmaceuticals's EBITDA was $2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 103.3% from the prior year.

Net Income

-$23.4M

YoY+73.4%

Mirum Pharmaceuticals reported -$23.4M in net income in fiscal year 2025. This represents an increase of 73.4% from the prior year.

EPS (Diluted)

$-0.47

YoY+74.6%

Mirum Pharmaceuticals earned $-0.47 per diluted share (EPS) in fiscal year 2025. This represents an increase of 74.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$54.9M

YoY+488.0%

Mirum Pharmaceuticals generated $54.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 488.0% from the prior year.

Cash & Debt

$296.7M

YoY+33.3%

5Y CAGR+15.9%

Mirum Pharmaceuticals held $296.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

52M

YoY+7.4%

5Y CAGR+11.8%

Mirum Pharmaceuticals had 52M shares outstanding in fiscal year 2025. This represents an increase of 7.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-4.3%

YoY+21.8pp

Mirum Pharmaceuticals's operating margin was -4.3% in fiscal year 2025, reflecting core business profitability. This is up 21.8 percentage points from the prior year.

Net Margin

-4.5%

YoY+21.6pp

Mirum Pharmaceuticals's net profit margin was -4.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 21.6 percentage points from the prior year.

Return on Equity

-7.4%

YoY+31.6pp

5Y CAGR+52.6pp

Mirum Pharmaceuticals's ROE was -7.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 31.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$186.2M

YoY+32.4%

5Y CAGR+17.9%

Mirum Pharmaceuticals invested $186.2M in research and development in fiscal year 2025. This represents an increase of 32.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$954K

YoY-3.9%

5Y CAGR+33.5%

Mirum Pharmaceuticals invested $954K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 3.9% from the prior year.

MIRM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$521.3M+54.7%	$336.9M+80.8%	$186.4M+141.8%	$77.1M+302.7%	$19.1M	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$186.2M+32.4%	$140.6M+37.1%	$102.6M-4.0%	$106.8M-18.7%	$131.4M+61.1%	$81.6M
SG&A Expenses	$257.0M+27.1%	$202.2M+38.6%	$145.9M+63.8%	$89.1M+50.4%	$59.2M+161.0%	$22.7M
Operating Income	-$22.1M+74.7%	-$87.6M+19.7%	-$109.2M+16.8%	-$131.2M+24.3%	-$173.4M-66.3%	-$104.3M
Interest Expense	$14.4M+0.5%	$14.3M-5.3%	$15.1M-5.5%	$16.0M	N/A	N/A
Income Tax	$1.9M+88.0%	$1.0M+3.9%	$991K+115.5%	-$6.4M-17413.5%	$37K+516.7%	$6K
Net Income	-$23.4M+73.4%	-$87.9M+46.2%	-$163.4M-20.5%	-$135.7M-61.5%	-$84.0M+18.7%	-$103.3M
EPS (Diluted)	$-0.47+74.6%	$-1.85+53.8%	$-4.00+0.5%	$-4.02-45.1%	$-2.77	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$148.9M+12.0%	$133.0M+4.1%	$127.8M+14.5%	$111.6M+12.2%	$99.4M+10.0%	$90.4M+16.1%	$77.9M+12.5%	$69.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$51.1M+19.0%	$43.0M-6.7%	$46.1M0.0%	$46.0M+4.6%	$44.0M+38.8%	$31.7M-2.9%	$32.7M+1.4%	$32.2M
SG&A Expenses	$74.1M+19.7%	$61.9M-2.2%	$63.3M+9.7%	$57.7M+1.5%	$56.8M+12.4%	$50.5M+2.7%	$49.2M+7.8%	$45.6M
Operating Income	-$4.6M-275.5%	$2.6M+152.2%	-$5.0M+67.1%	-$15.2M+37.3%	-$24.2M-91.0%	-$12.7M+47.7%	-$24.2M+8.4%	-$26.5M
Interest Expense	$3.6M-0.2%	$3.6M+0.5%	$3.6M-0.2%	$3.6M+0.5%	$3.6M-0.2%	$3.6M+0.5%	$3.6M-0.2%	$3.6M
Income Tax	$767K+392.7%	-$262K-165.2%	$402K-60.9%	$1.0M+278.6%	-$576K-266.0%	$347K-45.4%	$635K+1.8%	$624K
Net Income	-$5.7M-297.2%	$2.9M+149.6%	-$5.9M+60.1%	-$14.7M+38.3%	-$23.8M-67.1%	-$14.2M+42.2%	-$24.6M+2.5%	-$25.3M
EPS (Diluted)	N/A	$0.05+141.7%	$-0.12+60.0%	$-0.30	N/A	$-0.30+42.3%	$-0.52+3.7%	$-0.54

MIRM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$842.8M+25.7%	$670.8M+3.7%	$646.6M+83.2%	$352.9M+19.8%	$294.7M+22.3%	$240.9M
Current Assets	$549.7M+39.9%	$392.8M+1.4%	$387.5M+103.7%	$190.2M+14.2%	$166.6M-29.5%	$236.3M
Cash & Equivalents	$296.7M+33.3%	$222.5M-22.3%	$286.3M+922.5%	$28.0M-10.6%	$31.3M-77.9%	$142.1M
Inventory	$24.9M+11.1%	$22.4M+0.4%	$22.3M+300.9%	$5.6M+267.8%	$1.5M	$0
Accounts Receivable	$123.3M+57.5%	$78.3M+15.2%	$68.0M+183.3%	$24.0M+634.4%	$3.3M	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$528.1M+18.6%	$445.1M+11.9%	$398.0M+88.7%	$210.9M+20.9%	$174.4M+153.7%	$68.8M
Current Liabilities	$205.8M+62.6%	$126.6M+45.4%	$87.1M+34.5%	$64.7M+52.0%	$42.6M+130.7%	$18.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$314.7M+39.5%	$225.6M-9.3%	$248.7M+75.1%	$142.0M+18.2%	$120.2M-30.1%	$172.1M
Retained Earnings	-$667.5M-3.6%	-$644.2M-15.8%	-$556.2M-41.6%	-$392.8M-52.8%	-$257.2M-48.5%	-$173.2M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$842.8M+7.3%	$785.1M+8.2%	$725.8M+5.2%	$690.2M+2.9%	$670.8M+0.4%	$667.9M+1.1%	$660.8M+1.3%	$652.0M
Current Assets	$549.7M+3.6%	$530.6M+17.0%	$453.4M+10.4%	$410.8M+4.6%	$392.8M+1.6%	$386.6M+5.1%	$367.8M-5.6%	$389.5M
Cash & Equivalents	$296.7M+5.2%	$282.0M+23.6%	$228.1M+7.7%	$211.8M-4.8%	$222.5M-0.2%	$223.0M-4.4%	$233.2M-23.0%	$302.8M
Inventory	$24.9M+3.6%	$24.0M+4.7%	$22.9M+2.3%	$22.4M+0.1%	$22.4M+3.7%	$21.6M+5.7%	$20.4M-5.4%	$21.6M
Accounts Receivable	$123.3M+15.1%	$107.1M+0.3%	$106.8M+11.5%	$95.9M+22.4%	$78.3M+14.2%	$68.5M+13.4%	$60.4M+9.9%	$55.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$528.1M+7.1%	$493.1M+4.8%	$470.7M+3.0%	$457.0M+2.7%	$445.1M+2.1%	$435.9M+1.0%	$431.8M+3.5%	$417.4M
Current Liabilities	$205.8M+28.3%	$160.4M+10.7%	$144.8M+13.5%	$127.6M+0.8%	$126.6M+9.3%	$115.8M+3.1%	$112.3M+6.0%	$105.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$314.7M+7.8%	$292.0M+14.5%	$255.2M+9.4%	$233.3M+3.4%	$225.6M-2.8%	$232.0M+1.3%	$229.0M-2.4%	$234.6M
Retained Earnings	-$667.5M-0.9%	-$661.8M+0.4%	-$664.7M-0.9%	-$658.9M-2.3%	-$644.2M-3.8%	-$620.4M-2.3%	-$606.2M-4.2%	-$581.5M

MIRM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$55.8M+440.7%	$10.3M+114.6%	-$70.9M+40.9%	-$120.1M+9.5%	-$132.8M-49.0%	-$89.1M
Capital Expenditures	$954K-3.9%	$993K+811.0%	$109K-60.8%	$278K+1058.3%	$24K-89.3%	$225K
Free Cash Flow	$54.9M+488.0%	$9.3M+113.1%	-$71.1M+41.0%	-$120.4M+9.3%	-$132.8M-48.7%	-$89.3M
Investing Cash Flow	-$24.0M+73.4%	-$90.1M+15.9%	-$107.2M-1492.2%	$7.7M-84.1%	$48.5M+28.2%	$37.9M
Financing Cash Flow	$40.1M+126.8%	$17.7M-94.7%	$336.6M+208.6%	$109.1M+48.5%	$73.5M-59.5%	$181.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$6.1M-84.7%	$39.7M+229.6%	$12.0M+714.0%	-$2.0M+61.3%	-$5.1M-227.2%	$4.0M+204.8%	-$3.8M-125.0%	$15.2M
Capital Expenditures	$600K+220.9%	$187K+48.4%	$126K+207.3%	$41K+105.0%	$20K-89.0%	$181K-76.8%	$779K+5892.3%	$13K
Free Cash Flow	$5.5M-86.2%	$39.5M+231.5%	$11.9M+695.1%	-$2.0M+60.7%	-$5.1M-233.8%	$3.8M+183.0%	-$4.6M-130.1%	$15.2M
Investing Cash Flow	$1.0M+145.2%	-$2.2M+66.3%	-$6.6M+59.1%	-$16.1M-2617.0%	$641K+103.6%	-$18.0M+75.2%	-$72.7M-559261.5%	-$13K
Financing Cash Flow	$9.0M-44.1%	$16.1M+85.3%	$8.7M+36.6%	$6.4M+19.1%	$5.3M+38.2%	$3.9M-47.0%	$7.3M+505.1%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MIRM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-4.3%+21.8pp	-26.0%+32.6pp	-58.6%+111.7pp	-170.3%+735.8pp	-906.1%	N/A
Net Margin	-4.5%+21.6pp	-26.1%+61.6pp	-87.7%+88.4pp	-176.0%+262.8pp	-438.8%	N/A
Return on Equity	-7.4%+31.6pp	-39.0%+26.8pp	-65.7%+29.8pp	-95.5%-25.6pp	-69.9%-9.9pp	-60.0%
Return on Assets	-2.8%+10.3pp	-13.1%+12.2pp	-25.3%+13.2pp	-38.4%-9.9pp	-28.5%+14.4pp	-42.9%
Current Ratio	2.67-0.4	3.10-1.3	4.45+1.5	2.94-1.0	3.91-8.9	12.80
Debt-to-Equity	1.68-0.3	1.97+0.4	1.60+0.1	1.48+0.0	1.45+1.1	0.40
FCF Margin	10.5%+7.8pp	2.8%+40.9pp	-38.1%+118.1pp	-156.3%+537.6pp	-693.8%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-3.1%-5.0pp	2.0%+5.9pp	-3.9%+9.7pp	-13.6%+10.8pp	-24.4%-10.3pp	-14.0%+17.1pp	-31.1%+7.1pp	-38.2%
Net Margin	-3.9%-6.0pp	2.2%+6.8pp	-4.6%+8.6pp	-13.2%+10.8pp	-23.9%-8.2pp	-15.8%+15.9pp	-31.6%+4.9pp	-36.5%
Return on Equity	-1.8%-2.8pp	1.0%+3.3pp	-2.3%+4.0pp	-6.3%+4.3pp	-10.5%-4.4pp	-6.1%+4.6pp	-10.8%+0.0pp	-10.8%
Return on Assets	-0.7%-1.0pp	0.4%+1.2pp	-0.8%+1.3pp	-2.1%+1.4pp	-3.5%-1.4pp	-2.1%+1.6pp	-3.7%+0.2pp	-3.9%
Current Ratio	2.67-0.6	3.31+0.2	3.13-0.1	3.22+0.1	3.10-0.2	3.34+0.1	3.28-0.4	3.68
Debt-to-Equity	1.68-0.0	1.69-0.2	1.84-0.1	1.96-0.0	1.97+0.1	1.880.0	1.89+0.1	1.78
FCF Margin	3.7%-26.0pp	29.7%+20.4pp	9.3%+11.1pp	-1.8%+3.3pp	-5.1%-9.3pp	4.2%+10.1pp	-5.9%-27.8pp	22.0%

Similar Companies

Protagonist Ther PTGX

$6.6B

Ascentage Pharma Group International AAPG

$2.5B

Krystal Biotech KRYS

$7.6B

Metsera MTSR

$7.4B

Zai Lab Limited ZLAB

$2.3B

Frequently Asked Questions

What is Mirum Pharmaceuticals's annual revenue?

Mirum Pharmaceuticals (MIRM) reported $521.3M in total revenue for fiscal year 2025. This represents a 54.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Mirum Pharmaceuticals's revenue growing?

Mirum Pharmaceuticals (MIRM) revenue grew by 54.7% year-over-year, from $336.9M to $521.3M in fiscal year 2025.

Is Mirum Pharmaceuticals profitable?

No, Mirum Pharmaceuticals (MIRM) reported a net income of -$23.4M in fiscal year 2025, with a net profit margin of -4.5%.

What is Mirum Pharmaceuticals's EBITDA?

Mirum Pharmaceuticals (MIRM) had EBITDA of $2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Mirum Pharmaceuticals's operating margin?

Mirum Pharmaceuticals (MIRM) had an operating margin of -4.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Mirum Pharmaceuticals's net profit margin?

Mirum Pharmaceuticals (MIRM) had a net profit margin of -4.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Mirum Pharmaceuticals's return on equity (ROE)?

Mirum Pharmaceuticals (MIRM) has a return on equity of -7.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Mirum Pharmaceuticals's free cash flow?

Mirum Pharmaceuticals (MIRM) generated $54.9M in free cash flow during fiscal year 2025. This represents a 488.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Mirum Pharmaceuticals's operating cash flow?

Mirum Pharmaceuticals (MIRM) generated $55.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Mirum Pharmaceuticals's total assets?

Mirum Pharmaceuticals (MIRM) had $842.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Mirum Pharmaceuticals's capital expenditures?

Mirum Pharmaceuticals (MIRM) invested $954K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Mirum Pharmaceuticals spend on research and development?

Mirum Pharmaceuticals (MIRM) invested $186.2M in research and development during fiscal year 2025.

How many shares does Mirum Pharmaceuticals have outstanding?

Mirum Pharmaceuticals (MIRM) had 52M shares outstanding as of fiscal year 2025.

What is Mirum Pharmaceuticals's current ratio?

Mirum Pharmaceuticals (MIRM) had a current ratio of 2.67 as of fiscal year 2025, which is generally considered healthy.

What is Mirum Pharmaceuticals's debt-to-equity ratio?

Mirum Pharmaceuticals (MIRM) had a debt-to-equity ratio of 1.68 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Mirum Pharmaceuticals's return on assets (ROA)?

Mirum Pharmaceuticals (MIRM) had a return on assets of -2.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Mirum Pharmaceuticals's Piotroski F-Score?

Mirum Pharmaceuticals (MIRM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Mirum Pharmaceuticals's earnings high quality?

Mirum Pharmaceuticals (MIRM) has an earnings quality ratio of -2.39x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Mirum Pharmaceuticals cover its interest payments?

Mirum Pharmaceuticals (MIRM) has an interest coverage ratio of -1.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Mirum Pharmaceuticals?

Mirum Pharmaceuticals (MIRM) scores 47 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.